174565-63-0

Basic information

• Product Name: 7-nitroquinazoline-2,4(1H,3H)-dione
• Synonyms: 7-nitroquinazoline-2,4(1H,3H)-dione
• CAS NO: 174565-63-0
• Molecular Formula: C₈H₅N₃O₄
• Molecular Weight: 207.143
• Mol File: 174565-63-0.mol

Chemical Properties

• Melting Point: 350-355℃
• Appearance: /
• Density: 1.555±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.01±0.20(Predicted)
• CAS DataBase Reference: 7-nitroquinazoline-2,4(1H,3H)-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 7-nitroquinazoline-2,4(1H,3H)-dione(174565-63-0)
• EPA Substance Registry System: 7-nitroquinazoline-2,4(1H,3H)-dione(174565-63-0)

Safety Data

• Hazardous Substances Data: 174565-63-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
7-Nitroquinazoline-2,4(1H,3H)-dione is used as a reactant for the preparation of non-peptidic substrate-mimetic inhibitors of Akt. These inhibitors have potential as anti-cancer agents, targeting the Akt protein kinase to disrupt its role in promoting cell survival and proliferation, which is often dysregulated in cancer cells. This makes 7-nitroquinazoline-2,4(1H,3H)-dione a valuable component in the development of novel therapeutic strategies for cancer treatment.

Upstream product

• 1029420-40-3 C₁₁H₉N₃O₅ 
• 610-68-4 2-ureidobenzoic acid 
• 610-30-0 2,4-dinitrobenzoic acid 
• 917-61-3 sodium isocyanate 
• 619-17-0 4-Nitroanthranilic acid 
• 951-97-3 2-acetamido-4-nitrobenzoic acid 
• 2879-79-0 N-(2-methyl-5-nitrophenyl)acetamide 
• 7647-01-0 hydrogenchloride 
• 57-13-6 urea 
• 127099-85-8 N-Cyanoguanidine 

Downstream Products

• 1032373-44-6 1,3-dibenzyl-7-nitro-1H-quinazoline-2,4-dione 
• 1032373-45-7 1,3-dibenzyl-6-nitro-1H-quinazoline-2,4-dione 
• 129112-64-7 2-Chloro-7-nitro-4(3H)-quinazolinone 
• 129112-65-8 2,4-dichloro-7-nitroquinazoline 
• 59674-85-0 7-aminoquinazoline-2,4(1H,3H)-dione 

Relevant articles and documents

Oxidative cyclocondensation of cyclic thio(seleno)ureas. 4. Electronic effects of the substituents and the medium

We have studied the electronic effect of substituents, steric factors, the medium, and the nature of the oxidizing agent on oxidative cyclocondensation of 2-thioxo-4-quinazolone and its substituted derivatives. We have found that electron-donor substituents promote the reaction while electronacceptor substituents inhibit the reaction. 2006 Springer Science+Business Media, Inc.

INHIBITORS OF CYCLIN-DEPENDENT KINASES

Provided herein are compounds which are inhibitors of cyclin-dependent kinases (CDKs), pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.

Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments

Despite the rising threat of fatal coronaviruses, there are no general proven effective antivirals to treat them. 2-Aminoquinazolin-4(3H)-one derivatives were newly designed, synthesized, and investigated to show the inhibitory effects on SARS-CoV-2 and MERS-CoV. Among the synthesized derivatives, 7-chloro-2-((3,5-dichlorophenyl)amino)quinazolin-4(3H)-one (9g) and 2-((3,5-dichlorophenyl)amino)-5-hydroxyquinazolin-4 (3H)-one (11e) showed the most potent anti-SARS-CoV-2 activities (IC50 50 50 > 25 μM). In addition, both compounds showed acceptable results in metabolic stabilities, hERG binding affinities, CYP inhibitions, and preliminary PK studies.

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents

In this study, a series of novel 7 or 8-substituted 4-morpholine-quinazoline derivatives was designed and synthesized. Their PI3Kα inhibitory activities, antiproliferative activities against seven cancer cell lines, namely, PC-3, DU145, MCF-7, BT474, SK-BR-3, U937 and A431, were evaluated in vitro. Compound 17f proved to be a potential drug candidate with high PI3Kα inhibition activity (IC50 = 4.2 nM) and good antiproliferative activity. Compound 17f was also tested for its inhibitory activities against other kinases, such as PI3Kβ, PI3Kγ, PI3Kδ and mTOR, its effects on p-Akt (S473) and cell cycle. These results suggested that compound 17f could significantly inhibit the PI3K/Akt/mTOR pathway as a potent PI3K inhibitor and anticancer agent.

Condensation reaction of ethyl 4-oxo-4h-benzo[d][1,3]-oxazine-2- carboxylates with potassium cyanate: 2,4(1H,3H)-quinazolinediones synthesis

The condensation reaction of ethyl 4-oxo-4H-benzo[d][1,3]oxazine-2- carboxylates with acidic solution of potassium cyanate offers a novel and expedient route to the synthesis of 2,4(1H,3H)-quinazolinediones under mild reaction conditions..

The detection of glycine from the treatment of glyoxylic acid with iron(II) sulfate and ammonia in water

A glycine/(NH4)2SO4 mixture was isolated by treatment of glyoxylic acid with FeSO4 and aqNH3 in H2O. The yields of glycine were estimated by 1H NMR. Pyruvic acid was not reduced to alanine under these conditions. This method for forming glycine might have occurred prebiotically alongside the Urey-Miller arc discharge method for making amino acids because glyoxylic acid is formed by arc discharge through a N2/CO2 atmosphere and both NH3 and Fe(II) occurred in the earth's early oceans. The carboxylic acid directs the reduction of 2,4-dinitrobenzoic acid to give 2-amino-4-nitrobenzoic acid.

Fluorescent nucleoside analogue displays enhanced emission upon pairing with guanine

A fluorescent nucleobase analogue, 7-aminoquinazoline-2,4-(1H,3H)-dione, is incorporated into a DNA oligonucleotide and senses mismatched pairing by displaying G-specific fluorescence enhancement.

Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents

Akt has emerged as a critical target for the development of anti-cancer therapies. It has been found to be amplified, overexpressed, or constitutively activated in numerous human malignancies with oncogenesis derived from the simultaneous promotion of cell survival and suppression of apoptosis. A valuable alternative to the more common ATP-mimetic based chemotherapies is a substrate-mimetic approach, which has the potential advantage of inherent specificity of the substrate-binding pocket. In this paper we present the development of high affinity non-peptidic, substrate-mimetic inhibitors based on the minimum GSK3β substrate sequence. Optimization of initial peptidic leads resulted in the development of several classes of small molecule inhibitors, which have comparable potency to the initial peptidomimetics, while eliminating the remaining amino acid residues. We have identified the first non-peptidic substrate-mimetic lead inhibitors of Akt 29a-b, which have affinities of 17 and 12 μM, respectively. This strategy has potential to provide a useful set of molecular probes to assist in the validation of Akt as a potential target for anti-cancer drug design.

SUBSTRATE-MIMETIC AKT INHIBITOR

Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with 0 a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionallv homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterpartsand are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors.